NASDAQ:OCDX Ortho Clinical Diagnostics (OCDX) Stock Price, News & Analysis → Wall Street Legend Issues New NVDA Warning (From Chaikin Analytics) (Ad) Free OCDX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$17.63▼$17.6350-Day Range$17.63▼$17.6352-Week Range$16.04▼$22.99Volume5,400 shsAverage Volume1.24 million shsMarket Capitalization$3.92 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Ortho Clinical Diagnostics alerts: Email Address Ad Chaikin AnalyticsWall Street Legend Issues New NVDA WarningLegendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.Click here for the stock details About Ortho Clinical Diagnostics Stock (NASDAQ:OCDX)Ortho Clinical Diagnostics Holdings plc provides in-vitro diagnostics solutions to the clinical laboratory and transfusion medicine communities worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company is also involved in the provision of contract manufacturing and orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. Ortho Clinical Diagnostics Holdings plc was founded in 1939 and is headquartered in Raritan, New Jersey.Read More Ad Chaikin AnalyticsWall Street Legend Issues New NVDA WarningLegendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.Click here for the stock details OCDX Stock News HeadlinesAugust 22, 2023 | investing.comNovacyt: Innovative Clinical DiagnosticsAugust 9, 2023 | cbsnews.comFirst long COVID treatment clinical trials from NIH getting underwayApril 25, 2024 | Chaikin Analytics (Ad)Wall Street Legend Issues New NVDA WarningLegendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.March 18, 2023 | finance.yahoo.comClinical Diagnostics Global Market Report 2023: Sector to Reach $124.7 Billion by 2028 at a CAGR of 8.56%February 25, 2023 | marketwatch.comClinical Diagnostics Mass Spectrometry Market Brief Analysis By Top Leading CompaniesFebruary 25, 2023 | marketwatch.comClinical Diagnostics Market 2023 is FASTEST-GROWING in [ Medical Devices & Consumables ] Sector till 2028February 22, 2023 | marketwatch.comClinical Diagnostics Market Size in 2023 Business Forecast 2028 by Discovering LATEST TRENDSFebruary 18, 2023 | seekingalpha.comChitogenX announces $3.5M grant to advance ORTHO-R commercial developmentApril 25, 2024 | Chaikin Analytics (Ad)Wall Street Legend Issues New NVDA WarningLegendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.January 25, 2023 | marketwatch.comClinical Diagnostics Mass Spectrometry Market 2023 : Future Developments, Key Vendors, Regional Analysis and Industry Scope by 2029January 12, 2023 | finance.yahoo.comThe Worldwide Clinical Diagnostics Industry is Expected to Reach $93.6 Billion by 2027November 2, 2022 | finance.yahoo.comDr. James S. Lewis II, Antibiotic Susceptibility Test Expert, Joins as Chair of Selux Diagnostics' Clinical Advisory BoardOctober 14, 2022 | finance.yahoo.comGlobal Clinical Microbiology Instruments and Reagents Market Report 2022: Advancements in Molecular Diagnostics Drive GrowthSeptember 23, 2022 | finance.yahoo.comBrightInsight and bioMérieux Announce Partnership to Launch Clinical Digital Solutions for DiagnosticsMay 7, 2022 | seekingalpha.comOrtho Clinical Diagnostics Holdings PLC (OCDX) CEO Chris Smith on Q1 2022 Results - Earnings Call TranscriptMay 5, 2022 | fool.comOrtho Clinical Diagnostics Holdings plc (OCDX) Q1 2022 Earnings Call TranscriptMay 5, 2022 | seekingalpha.comOrtho Clinical Diagnostics Holdings plc 2022 Q1 - Results - Earnings Call PresentationMay 4, 2022 | finance.yahoo.comOrtho Clinical Diagnostics (OCDX) Q1 Earnings Top EstimatesMay 4, 2022 | seekingalpha.comOrtho Clinical Diagnostics Non-GAAP EPS of $0.23 beats by $0.03, revenue of $495M misses by $12.41MMay 4, 2022 | finance.yahoo.comOrtho Clinical Diagnostics Reports First Quarter 2022 ResultsApril 28, 2022 | finance.yahoo.comWhy Ortho Clinical (OCDX) Could Beat Earnings Estimates AgainApril 27, 2022 | finance.yahoo.comOrtho Clinical Diagnostics (OCDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseApril 26, 2022 | finance.yahoo.comOrtho Clinical Diagnostics Recognized with Fifth Prestigious Edison Award for Highly Accurate COVID-19 SolutionApril 20, 2022 | finance.yahoo.comOrtho Clinical Diagnostics to Report First Quarter 2022 Results on May 4, 2022March 24, 2022 | finance.yahoo.comOrtho Clinical (OCDX) Upgraded to Strong Buy: Here's What You Should KnowMarch 11, 2022 | finance.yahoo.comWall Street Analysts Predict a 58% Upside in Ortho Clinical (OCDX): Here's What You Should KnowMarch 9, 2022 | finance.yahoo.comOrtho Clinical Diagnostics Wins Bronze Stevie® Award for Customer Service and SupportSee More Headlines Receive OCDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ortho Clinical Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/03/2021Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic Substances Sub-IndustryN/A Current SymbolNASDAQ:OCDX CUSIPN/A CIK1828443 Webwww.orthoclinicaldiagnostics.com Phone908-218-8000FaxN/AEmployees4,800Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E Ratio21.77 P/E Growth1.66Net Income$-54,300,000.00 Net Margins-0.02% Pretax Margin1.38% Return on Equity41.71% Return on Assets5.10% Debt Debt-to-Equity Ratio4.91 Current Ratio1.89 Quick Ratio1.29 Sales & Book Value Annual Sales$2.04 billion Price / Sales1.92 Cash Flow$2.28 per share Price / Cash Flow7.73 Book Value$1.99 per share Price / Book8.86Miscellaneous Outstanding Shares222,585,000Free FloatN/AMarket Cap$3.92 billion OptionableNot Optionable Beta1.32 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Christopher Michael Smith (Age 59)Chairman & CEO Comp: $2.85MMr. Joseph M. Busky CPA (Age 54)Chief Financial Officer Comp: $607.06kMr. Michael A. Schlesinger (Age 63)Exec. VP, Gen. Counsel & Sec. Comp: $879.13kMr. Michael S. Iskra (Age 52)Exec. VP of Commercial Excellence & Strategy Comp: $760.23kDr. Chockalingam Palaniappan Ph.D. (Age 57)Chief Innovation Officer Comp: $826.63kMs. Ariane SchiereckChief Information OfficerMr. Marwan FathallahHead of Quality, Regulatory, Compliance, Clinical, Medical & Scientific AffairsMr. Gary PassmanHead of People & CultureKaren TaylorHead of Global Commercial EnablementMr. Warren StoneHead of AmericasMore ExecutivesKey CompetitorsLantheusNASDAQ:LNTHNeogenNASDAQ:NEOGQuidelOrthoNASDAQ:QDELCelldex TherapeuticsNASDAQ:CLDXIntellia TherapeuticsNASDAQ:NTLAView All Competitors OCDX Stock Analysis - Frequently Asked Questions How were Ortho Clinical Diagnostics' earnings last quarter? Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) issued its earnings results on Wednesday, November, 3rd. The company reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.07. The company had revenue of $522.50 million for the quarter, compared to analyst estimates of $485.36 million. Ortho Clinical Diagnostics had a negative net margin of 0.02% and a positive trailing twelve-month return on equity of 41.71%. When did Ortho Clinical Diagnostics IPO? Ortho Clinical Diagnostics (OCDX) raised $1.5 billion in an IPO on Thursday, January 28th 2021. The company issued 70,000,000 shares at $20.00-$23.00 per share. J.P. Morgan, BofA Securities, Goldman Sachs, Barclays and Morgan Stanley served as the underwriters for the IPO and Citigroup, Credit Suisse, UBS Investment Bank, Evercore ISI, Piper Sandler, ING, Macquarie Capital, Nomura, TCG Capital Markets, Drexel Hamilton, H.C. Wainwright & Co., Ramirez & Co. and Siebert Williams Shank were co-managers. This page (NASDAQ:OCDX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWall Street Legend Issues New NVDA WarningChaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternativetop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ortho Clinical Diagnostics Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
